Highest-materiality recent filing
Cypherpunk Q1 net loss $77.2M as $77.6M unrealized ZEC loss hits earnings
Net loss $77.2M vs $15.4M YoY; $77.6M unrealized loss on ZEC marked to market.
Cypherpunk reports FY2025 net income of $4.8M; ZEC treasury at $147.4M
Net income of $4.8M vs net loss of $67.8M in 2024; driven by $50.4M unrealized gain on ZEC holdings.
Nasdaq notified Cypherpunk that its common stock closing bid price was below $1.00 for 30 consecutive business days.
Cypherpunk buys additional 56,418 ZEC for ~$29M, total holdings reach 290,063 ZEC (1.76% of supply)
Purchased 56,418.09 ZEC at $514.02/ZEC for ~$29 million.
Cypherpunk grants 5.45M RSUs to consultant CoinXit; cancels prior award
Granted 5,448,157 RSUs under 2025 Equity Incentive Plan; cancels prior 2,411,700 RSUs under 2022 Plan.
Stockholders approved the 2025 Equity Incentive Plan covering up to 31,454,785 shares of common stock.
Cypherpunk Technologies (CYPH) signed a waiver agreement with Winklevoss Capital on November 19, 2025, modifying the October 8, 2025 common warrant.
Cypherpunk buys additional $18M of Zcash, now holds 1.43% of network
Purchased 29,869.29 ZEC for $18M at average price $602.63/ZEC on November 18, 2025.
Leap Therapeutics rebrands as Cypherpunk, buys $50M ZEC, appoints new leaders
Company renamed Cypherpunk Technologies; stock ticker changes from LPTX to CYPH on Nov 13, 2025.
Company entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. to sell up to $200M of common stock.
Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025
In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).
Gross proceeds of ~$58.88M from sale of 15.2M shares, 80.8M pre-funded warrants, and 72.0M common warrants.
$58,888,888 in cash commitments for PIPE offering at $0.61439 per unit, led by Winklevoss Capital.
Leap Therapeutics gets Nasdaq bid price extension to March 9, 2026
Nasdaq granted additional 180-day compliance period until March 9, 2026, for minimum $1.00 bid price.
Leap Therapeutics Q2 net loss $16.6M, cuts workforce 75%, explores strategic alternatives
Net loss of $16.6M for Q2 2025 vs $20.4M in Q2 2024; cash and equivalents $18.1M at June 30, 2025.
Leap reports sirexatamab PFS benefit in CRC subgroups; workforce cut 75%, strategic review
DeFianCe study: in high-DKK1 pts (upper quartile), median PFS 9.36 vs 5.88 mo (HR 0.47, p=0.024); ORR 44% vs 15.8% (p=0.015).
Cyndi Sirard, MD will be terminated without cause from her position as the Company’s Chief Medical Officer, effective on or about July 31, 2025
Augustine Lawlor will be terminated without cause from his position as the Company’s Chief Operating Officer, effective June 30, 2025
Max materiality 1.00 · Median 0.70 · Most common event other_material